Inflammatory markers at baseline correlate with subsequent clinical response to quetiapine in patients with bipolar disorder.

The reported results, although preliminary, could be useful in clinical practice, providing not only markers for QUE response, but also allowing for identification of new targets and new therapies for the treatment of this condition.